Yael Renert-Yuval1, Ester Del Duca2, Ana B Pavel3, Milie Fang4, Rachel Lefferdink4, Jianni Wu5, Aisleen Diaz5, Yeriel D Estrada5, Talia Canter4, Ning Zhang5, Annette Wagner4, Sarah Chamlin4, James G Krueger6, Emma Guttman-Yassky7, Amy S Paller8. 1. Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY; Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY. 2. Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Dermatology, University Magna Graecia, Catanzaro, Italy. 3. Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Biomedical Engineering, University of Mississippi, Oxford, Miss. 4. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Ill. 5. Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY. 6. Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY. 7. Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY; Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: Emma.Guttman@mountsinai.org. 8. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Ill. Electronic address: apaller@northwestern.edu.
Abstract
BACKGROUND: Although atopic dermatitis (AD) often presents in infancy and persists into adulthood, comparative characterization of AD skin among different pediatric age groups is lacking. OBJECTIVE: We sought to define skin biopsy profiles of lesional and nonlesional AD across different age groups (0-5-year-old infants with disease duration <6 months, 6-11-year-old children, 12-17-year-old adolescents, ≥18-year-old adults) versus age-appropriate controls. METHODS: We performed gene expression analyses by RNA-sequencing and real-time PCR (RT-PCR) and protein expression analysis using immunohistochemistry. RESULTS: TH2/TH22 skewing, including IL-13, CCL17/thymus and activation-regulated chemokine, IL-22, and S100As, characterized the common AD signature, with a global pathway-level enrichment across all ages. Nevertheless, specific cytokines varied widely. For example, IL-33, IL-1RL1/IL-33R, and IL-9, often associated with early atopic sensitization, showed greatest upregulations in infants. TH17 inflammation presented a 2-peak curve, with highest increases in infants (including IL-17A and IL-17F), followed by adults. TH1 polarization was uniquely detected in adults, even when compared with adolescents, with significant upregulation in adults of IFN-γ and CXCL9/CXCL10/CXCL11. Although all AD age groups had barrier abnormalities, only adults had significant decreases in filaggrin expression. Despite the short duration of the disease, infant AD presented robust downregulations of multiple barrier-related genes in both lesional and nonlesional skin. Clinical severity scores significantly correlated with TH2/TH22-related markers in all pediatric age groups. CONCLUSIONS: The shared signature of AD across ages is TH2/TH22-skewed, yet differential expression of specific TH2/TH22-related genes, other TH pathways, and barrier-related genes portray heterogenetic, age-specific molecular fingerprints.
BACKGROUND: Although atopic dermatitis (AD) often presents in infancy and persists into adulthood, comparative characterization of AD skin among different pediatric age groups is lacking. OBJECTIVE: We sought to define skin biopsy profiles of lesional and nonlesional AD across different age groups (0-5-year-old infants with disease duration <6 months, 6-11-year-old children, 12-17-year-old adolescents, ≥18-year-old adults) versus age-appropriate controls. METHODS: We performed gene expression analyses by RNA-sequencing and real-time PCR (RT-PCR) and protein expression analysis using immunohistochemistry. RESULTS: TH2/TH22 skewing, including IL-13, CCL17/thymus and activation-regulated chemokine, IL-22, and S100As, characterized the common AD signature, with a global pathway-level enrichment across all ages. Nevertheless, specific cytokines varied widely. For example, IL-33, IL-1RL1/IL-33R, and IL-9, often associated with early atopic sensitization, showed greatest upregulations in infants. TH17 inflammation presented a 2-peak curve, with highest increases in infants (including IL-17A and IL-17F), followed by adults. TH1 polarization was uniquely detected in adults, even when compared with adolescents, with significant upregulation in adults of IFN-γ and CXCL9/CXCL10/CXCL11. Although all AD age groups had barrier abnormalities, only adults had significant decreases in filaggrin expression. Despite the short duration of the disease, infant AD presented robust downregulations of multiple barrier-related genes in both lesional and nonlesional skin. Clinical severity scores significantly correlated with TH2/TH22-related markers in all pediatric age groups. CONCLUSIONS: The shared signature of AD across ages is TH2/TH22-skewed, yet differential expression of specific TH2/TH22-related genes, other TH pathways, and barrier-related genes portray heterogenetic, age-specific molecular fingerprints.
Authors: Jeff E Mold; Shivkumar Venkatasubrahmanyam; Trevor D Burt; Jakob Michaëlsson; Jose M Rivera; Sofiya A Galkina; Kenneth Weinberg; Cheryl A Stoddart; Joseph M McCune Journal: Science Date: 2010-12-17 Impact factor: 47.728
Authors: Eric L Simpson; Carsten Flohr; Lawrence F Eichenfield; Thomas Bieber; Howard Sofen; Alain Taïeb; Ryan Owen; Wendy Putnam; Marcela Castro; Kendra DeBusk; Chin-Yu Lin; Athina Voulgari; Karl Yen; Theodore A Omachi Journal: J Am Acad Dermatol Date: 2018-01-17 Impact factor: 11.527
Authors: Aaron R Turkish; Annette L Henneberry; Debra Cromley; Mahajabeen Padamsee; Peter Oelkers; Hisham Bazzi; Angela M Christiano; Jeffrey T Billheimer; Stephen L Sturley Journal: J Biol Chem Date: 2005-01-25 Impact factor: 5.157
Authors: Derek K Chu; Alba Llop-Guevara; Tina D Walker; Kristin Flader; Susanna Goncharova; Jeanette E Boudreau; Cheryl Lynn Moore; Tracy Seunghyun In; Susan Waserman; Anthony J Coyle; Roland Kolbeck; Alison A Humbles; Manel Jordana Journal: J Allergy Clin Immunol Date: 2012-09-21 Impact factor: 10.793
Authors: Stacey R Dillon; Cindy Sprecher; Angela Hammond; Janine Bilsborough; Maryland Rosenfeld-Franklin; Scott R Presnell; Harald S Haugen; Mark Maurer; Brandon Harder; Janet Johnston; Susan Bort; Sherri Mudri; Joseph L Kuijper; Tom Bukowski; Pamela Shea; Dennis L Dong; Maria Dasovich; Francis J Grant; Luann Lockwood; Steven D Levin; Cosette LeCiel; Kim Waggie; Heather Day; Stavros Topouzis; Janet Kramer; Rolf Kuestner; Zhi Chen; Don Foster; Julia Parrish-Novak; Jane A Gross Journal: Nat Immunol Date: 2004-06-06 Impact factor: 25.606
Authors: L Yi; D Cheng; K Zhang; X Huo; Y Mo; H Shi; H Di; Y Zou; H Zhang; J Zhao; Y Xu; D J Erle; G Zhen Journal: Mucosal Immunol Date: 2017-02-22 Impact factor: 7.313
Authors: D J Margolis; N Mitra; J L Duke; R Berna; J D Margolis; O Hoffstad; B S Kim; A C Yan; A L Zaenglein; Z Chiesa Fuxench; A Dinou; J Wasserman; N Tairis; T L Mosbruger; D Ferriola; Georgios Damianos; Ioanna Kotsopoulou; D S Monos Journal: Hum Immunol Date: 2021-04-17 Impact factor: 2.211
Authors: Petra Pavel; Stefan Blunder; Verena Moosbrugger-Martinz; Peter M Elias; Sandrine Dubrac Journal: Int J Mol Sci Date: 2022-02-14 Impact factor: 5.923